Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: Byvasda

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Etana Biotechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 19, 2021

            Details:

            Etana is committed to launch BYVASDA® in the local market. In return, Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bevacizumab

            Therapeutic Area: Oncology Product Name: Byvasda

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 28, 2020

            Details:

            BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the NMPA of China for the treatment of adult recurrent glioblastoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Orelabrutinib

            Therapeutic Area: Oncology Product Name: ICP-022

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 27, 2020

            Details:

            Orelabrutinib is a highly selective and novel BTK inhibitor developed by InnoCare that can avoid off-target-related adverse events with improved safety and efficacy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ropeginterferon ALFA-2B

            Therapeutic Area: Oncology Product Name: P1101

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 07, 2020

            Details:

            Five-year data from the PROUD-PV/CONTINUATION-PV studies demonstrates the shortand long-term effects of ropeginterferon alfa-2b among PV patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Denosumab

            Therapeutic Area: Oncology Product Name: Xgeva

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            The approval of XGEVA for the prevention of SREs in patients with bone metastasis from solid tumors and MM was based on clinical results from four randomized international trials that enrolled over 7,000 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ivosidenib

            Therapeutic Area: Oncology Product Name: Tibsovo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Agios Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            Ivosidenib, an oral, targeted inhibitor of the IDH1 enzyme, is globally the first and only US FDA-approved therapy for patients with R/R AML and an IDH1 mutation. Ivosidenib was developed by Agios Pharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ropeginterferon ALFA-2B

            Therapeutic Area: Oncology Product Name: Besremi

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Findings from “Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension” will be featured as an oral presentation at the Virtual ASH Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Halpryza

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            Halpryza (rituximab injection) is Innovent’s fourth monoclonal antibody drug approved by the NMPA following TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sintilimab

            Therapeutic Area: Oncology Product Name: Tyvyt

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: $200.0 million

            Deal Type: Collaboration October 07, 2020

            Details:

            Innovent Biologics announce the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with global expansion collaboration agreement between the company and Eli Lilly for TYVYT (sintilimab injection).